nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Clofarabine—hematologic cancer	0.133	0.247	CrCtD
Regadenoson—Nelarabine—hematologic cancer	0.125	0.233	CrCtD
Regadenoson—Fludarabine—hematologic cancer	0.0975	0.182	CrCtD
Regadenoson—Cytarabine—hematologic cancer	0.0921	0.171	CrCtD
Regadenoson—Cladribine—hematologic cancer	0.0898	0.167	CrCtD
Regadenoson—Adenosine triphosphate—Nelarabine—hematologic cancer	0.00995	0.0271	CrCrCtD
Regadenoson—Ribavirin—Clofarabine—hematologic cancer	0.00981	0.0268	CrCrCtD
Regadenoson—Ribavirin—Nelarabine—hematologic cancer	0.00922	0.0252	CrCrCtD
Regadenoson—S-Adenosylmethionine—Clofarabine—hematologic cancer	0.00915	0.025	CrCrCtD
Regadenoson—Clofarabine—Nelarabine—hematologic cancer	0.0086	0.0235	CrCrCtD
Regadenoson—S-Adenosylmethionine—Nelarabine—hematologic cancer	0.0086	0.0235	CrCrCtD
Regadenoson—Fludarabine—Clofarabine—hematologic cancer	0.00858	0.0234	CrCrCtD
Regadenoson—Vidarabine—Pentostatin—hematologic cancer	0.00815	0.0222	CrCrCtD
Regadenoson—Cladribine—Pentostatin—hematologic cancer	0.00815	0.0222	CrCrCtD
Regadenoson—Azacitidine—Pentostatin—hematologic cancer	0.00815	0.0222	CrCrCtD
Regadenoson—Adenosine—Pentostatin—hematologic cancer	0.00815	0.0222	CrCrCtD
Regadenoson—Adenosine monophosphate—Clofarabine—hematologic cancer	0.00809	0.0221	CrCrCtD
Regadenoson—Nelarabine—Clofarabine—hematologic cancer	0.00809	0.0221	CrCrCtD
Regadenoson—Fludarabine—Nelarabine—hematologic cancer	0.00807	0.022	CrCrCtD
Regadenoson—Adenosine triphosphate—Fludarabine—hematologic cancer	0.00777	0.0212	CrCrCtD
Regadenoson—Cytarabine—Clofarabine—hematologic cancer	0.00765	0.0209	CrCrCtD
Regadenoson—Adenosine monophosphate—Nelarabine—hematologic cancer	0.0076	0.0207	CrCrCtD
Regadenoson—Cladribine—Clofarabine—hematologic cancer	0.00727	0.0198	CrCrCtD
Regadenoson—Azacitidine—Clofarabine—hematologic cancer	0.00727	0.0198	CrCrCtD
Regadenoson—Adenosine—Clofarabine—hematologic cancer	0.00727	0.0198	CrCrCtD
Regadenoson—Vidarabine—Clofarabine—hematologic cancer	0.00727	0.0198	CrCrCtD
Regadenoson—Ribavirin—Fludarabine—hematologic cancer	0.0072	0.0196	CrCrCtD
Regadenoson—Cytarabine—Nelarabine—hematologic cancer	0.00719	0.0196	CrCrCtD
Regadenoson—Azacitidine—Nelarabine—hematologic cancer	0.00683	0.0186	CrCrCtD
Regadenoson—Adenosine—Nelarabine—hematologic cancer	0.00683	0.0186	CrCrCtD
Regadenoson—Vidarabine—Nelarabine—hematologic cancer	0.00683	0.0186	CrCrCtD
Regadenoson—Cladribine—Nelarabine—hematologic cancer	0.00683	0.0186	CrCrCtD
Regadenoson—Ribavirin—Cytarabine—hematologic cancer	0.0068	0.0185	CrCrCtD
Regadenoson—Clofarabine—Fludarabine—hematologic cancer	0.00671	0.0183	CrCrCtD
Regadenoson—S-Adenosylmethionine—Fludarabine—hematologic cancer	0.00671	0.0183	CrCrCtD
Regadenoson—Clofarabine—Cytarabine—hematologic cancer	0.00634	0.0173	CrCrCtD
Regadenoson—S-Adenosylmethionine—Cytarabine—hematologic cancer	0.00634	0.0173	CrCrCtD
Regadenoson—Clofarabine—Cladribine—hematologic cancer	0.00618	0.0169	CrCrCtD
Regadenoson—Fludarabine—Cytarabine—hematologic cancer	0.00595	0.0162	CrCrCtD
Regadenoson—Nelarabine—Fludarabine—hematologic cancer	0.00593	0.0162	CrCrCtD
Regadenoson—Adenosine monophosphate—Fludarabine—hematologic cancer	0.00593	0.0162	CrCrCtD
Regadenoson—Fludarabine—Cladribine—hematologic cancer	0.0058	0.0158	CrCrCtD
Regadenoson—Cytarabine—Fludarabine—hematologic cancer	0.00562	0.0153	CrCrCtD
Regadenoson—Nelarabine—Cytarabine—hematologic cancer	0.0056	0.0153	CrCrCtD
Regadenoson—Adenosine monophosphate—Cytarabine—hematologic cancer	0.0056	0.0153	CrCrCtD
Regadenoson—Nelarabine—Cladribine—hematologic cancer	0.00546	0.0149	CrCrCtD
Regadenoson—Adenosine monophosphate—Cladribine—hematologic cancer	0.00546	0.0149	CrCrCtD
Regadenoson—Azacitidine—Fludarabine—hematologic cancer	0.00533	0.0146	CrCrCtD
Regadenoson—Vidarabine—Fludarabine—hematologic cancer	0.00533	0.0146	CrCrCtD
Regadenoson—Cladribine—Fludarabine—hematologic cancer	0.00533	0.0146	CrCrCtD
Regadenoson—Adenosine—Fludarabine—hematologic cancer	0.00533	0.0146	CrCrCtD
Regadenoson—Cytarabine—Gemcitabine—hematologic cancer	0.0053	0.0145	CrCrCtD
Regadenoson—Adenosine—Cytarabine—hematologic cancer	0.00504	0.0137	CrCrCtD
Regadenoson—Vidarabine—Cytarabine—hematologic cancer	0.00504	0.0137	CrCrCtD
Regadenoson—Azacitidine—Cytarabine—hematologic cancer	0.00504	0.0137	CrCrCtD
Regadenoson—Azacitidine—Gemcitabine—hematologic cancer	0.00504	0.0137	CrCrCtD
Regadenoson—Adenosine—Cladribine—hematologic cancer	0.00491	0.0134	CrCrCtD
Regadenoson—Vidarabine—Cladribine—hematologic cancer	0.00491	0.0134	CrCrCtD
Regadenoson—Azacitidine—Cladribine—hematologic cancer	0.00491	0.0134	CrCrCtD
Regadenoson—ADORA2A—hematopoietic system—hematologic cancer	0.000323	0.337	CbGeAlD
Regadenoson—Azacitidine—DNMT3A—hematologic cancer	0.00032	0.12	CrCbGaD
Regadenoson—Azacitidine—CDA—hematologic cancer	0.000285	0.107	CrCbGaD
Regadenoson—ADORA2A—gonad—hematologic cancer	0.000246	0.256	CbGeAlD
Regadenoson—Nelarabine—DCK—hematologic cancer	0.000236	0.0887	CrCbGaD
Regadenoson—Clofarabine—DCK—hematologic cancer	0.000229	0.0863	CrCbGaD
Regadenoson—Fludarabine—DCK—hematologic cancer	0.000222	0.0836	CrCbGaD
Regadenoson—ADORA2A—blood—hematologic cancer	0.000214	0.223	CbGeAlD
Regadenoson—ADORA2A—testis—hematologic cancer	0.000177	0.184	CbGeAlD
Regadenoson—Adenosine triphosphate—ASNS—hematologic cancer	0.000168	0.0632	CrCbGaD
Regadenoson—Cytarabine—CDA—hematologic cancer	0.000163	0.0612	CrCbGaD
Regadenoson—Adenosine monophosphate—CREB1—hematologic cancer	0.000147	0.0552	CrCbGaD
Regadenoson—Cytarabine—DCK—hematologic cancer	0.000143	0.0539	CrCbGaD
Regadenoson—Cladribine—DCK—hematologic cancer	0.000132	0.0496	CrCbGaD
Regadenoson—Adenosine triphosphate—ABL2—hematologic cancer	0.000127	0.0479	CrCbGaD
Regadenoson—Adenosine triphosphate—ALK—hematologic cancer	7.71e-05	0.029	CrCbGaD
Regadenoson—Adenosine triphosphate—AKT1—hematologic cancer	6.02e-05	0.0226	CrCbGaD
Regadenoson—Adenosine monophosphate—SRC—hematologic cancer	5.93e-05	0.0223	CrCbGaD
Regadenoson—Adenosine triphosphate—ABL1—hematologic cancer	5.68e-05	0.0214	CrCbGaD
Regadenoson—Adenosine monophosphate—PDE4B—hematologic cancer	5.3e-05	0.0199	CrCbGaD
Regadenoson—Clofarabine—ABCG2—hematologic cancer	5.17e-05	0.0195	CrCbGaD
Regadenoson—Cytarabine—SLC22A1—hematologic cancer	4.62e-05	0.0174	CrCbGaD
Regadenoson—Cladribine—SLC22A1—hematologic cancer	4.25e-05	0.016	CrCbGaD
Regadenoson—Cladribine—ABCG2—hematologic cancer	2.97e-05	0.0112	CrCbGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—hematologic cancer	2.49e-05	0.00233	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—TSC2—hematologic cancer	2.47e-05	0.00231	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—JAK3—hematologic cancer	2.42e-05	0.00227	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RGS2—hematologic cancer	2.41e-05	0.00225	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF2—hematologic cancer	2.39e-05	0.00223	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—TRH—hematologic cancer	2.38e-05	0.00223	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—TRIO—hematologic cancer	2.38e-05	0.00223	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGFR3—hematologic cancer	2.37e-05	0.00222	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3R1—hematologic cancer	2.35e-05	0.0022	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK14—hematologic cancer	2.35e-05	0.0022	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR7—hematologic cancer	2.32e-05	0.00217	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL13—hematologic cancer	2.32e-05	0.00217	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—LPAR1—hematologic cancer	2.3e-05	0.00216	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—JAK2—hematologic cancer	2.29e-05	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL3RA—hematologic cancer	2.27e-05	0.00212	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—BAD—hematologic cancer	2.25e-05	0.00211	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NFKBIA—hematologic cancer	2.25e-05	0.00211	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—hematologic cancer	2.23e-05	0.00209	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HDAC11—hematologic cancer	2.22e-05	0.00208	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RGS2—hematologic cancer	2.19e-05	0.00204	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CD80—hematologic cancer	2.18e-05	0.00204	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KIT—hematologic cancer	2.18e-05	0.00204	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—hematologic cancer	2.17e-05	0.00203	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—hematologic cancer	2.17e-05	0.00203	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—TRIO—hematologic cancer	2.16e-05	0.00202	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—TRH—hematologic cancer	2.16e-05	0.00202	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTPN11—hematologic cancer	2.14e-05	0.002	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BCR—hematologic cancer	2.13e-05	0.00199	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PDE4B—hematologic cancer	2.12e-05	0.00198	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CNR2—hematologic cancer	2.12e-05	0.00198	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—LPAR1—hematologic cancer	2.09e-05	0.00196	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RAC2—hematologic cancer	2.09e-05	0.00195	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CREB1—hematologic cancer	2.07e-05	0.00194	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—BRAF—hematologic cancer	2.05e-05	0.00192	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—hematologic cancer	2.04e-05	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6R—hematologic cancer	2.02e-05	0.00189	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADCY7—hematologic cancer	1.99e-05	0.00187	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HDAC10—hematologic cancer	1.98e-05	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—JUN—hematologic cancer	1.98e-05	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAP2K1—hematologic cancer	1.93e-05	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PDE4B—hematologic cancer	1.93e-05	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CNR2—hematologic cancer	1.93e-05	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CD—hematologic cancer	1.92e-05	0.00179	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PTEN—hematologic cancer	1.91e-05	0.00179	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RAC2—hematologic cancer	1.89e-05	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	1.89e-05	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—hematologic cancer	1.88e-05	0.00176	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—hematologic cancer	1.88e-05	0.00176	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—MAPK8—hematologic cancer	1.87e-05	0.00175	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGF2—hematologic cancer	1.83e-05	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—EP300—hematologic cancer	1.82e-05	0.00171	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ARHGEF12—hematologic cancer	1.81e-05	0.00169	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADCY7—hematologic cancer	1.81e-05	0.00169	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3R1—hematologic cancer	1.81e-05	0.00169	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTHLH—hematologic cancer	1.8e-05	0.00169	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ARHGEF1—hematologic cancer	1.77e-05	0.00165	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—JAK2—hematologic cancer	1.76e-05	0.00164	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTGER4—hematologic cancer	1.76e-05	0.00164	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—hematologic cancer	1.74e-05	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MDM2—hematologic cancer	1.72e-05	0.00161	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—hematologic cancer	1.68e-05	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—hematologic cancer	1.67e-05	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CB—hematologic cancer	1.67e-05	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MTOR—hematologic cancer	1.67e-05	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL3—hematologic cancer	1.66e-05	0.00155	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTHLH—hematologic cancer	1.64e-05	0.00153	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—hematologic cancer	1.6e-05	0.0015	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTGER4—hematologic cancer	1.59e-05	0.00149	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGRN—hematologic cancer	1.58e-05	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL17—hematologic cancer	1.58e-05	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1B—hematologic cancer	1.57e-05	0.00147	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCR5—hematologic cancer	1.55e-05	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCR4—hematologic cancer	1.55e-05	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—hematologic cancer	1.54e-05	0.00144	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEF1—hematologic cancer	1.53e-05	0.00143	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNA13—hematologic cancer	1.5e-05	0.0014	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL3—hematologic cancer	1.5e-05	0.0014	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TIAM1—hematologic cancer	1.48e-05	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1A—hematologic cancer	1.45e-05	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RASGRP1—hematologic cancer	1.45e-05	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTEN—hematologic cancer	1.44e-05	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—hematologic cancer	1.44e-05	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL2—hematologic cancer	1.44e-05	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAK3—hematologic cancer	1.43e-05	0.00134	CbGpPWpGaD
Regadenoson—Rash—Irinotecan—hematologic cancer	1.42e-05	0.000173	CcSEcCtD
Regadenoson—Dermatitis—Mitoxantrone—hematologic cancer	1.42e-05	0.000173	CcSEcCtD
Regadenoson—Dermatitis—Irinotecan—hematologic cancer	1.42e-05	0.000173	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MAPK8—hematologic cancer	1.41e-05	0.00132	CbGpPWpGaD
Regadenoson—Headache—Irinotecan—hematologic cancer	1.41e-05	0.000172	CcSEcCtD
Regadenoson—Headache—Mitoxantrone—hematologic cancer	1.41e-05	0.000172	CcSEcCtD
Regadenoson—Nausea—Ifosfamide—hematologic cancer	1.41e-05	0.000172	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CXCR4—hematologic cancer	1.41e-05	0.00132	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.4e-05	0.000171	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.4e-05	0.000171	CcSEcCtD
Regadenoson—Myalgia—Prednisone—hematologic cancer	1.4e-05	0.000171	CcSEcCtD
Regadenoson—Arthralgia—Prednisone—hematologic cancer	1.4e-05	0.000171	CcSEcCtD
Regadenoson—Feeling abnormal—Triamcinolone—hematologic cancer	1.4e-05	0.000171	CcSEcCtD
Regadenoson—Diarrhoea—Cisplatin—hematologic cancer	1.4e-05	0.000171	CcSEcCtD
Regadenoson—Anxiety—Prednisone—hematologic cancer	1.4e-05	0.00017	CcSEcCtD
Regadenoson—Vomiting—Gemcitabine—hematologic cancer	1.39e-05	0.00017	CcSEcCtD
Regadenoson—Insomnia—Betamethasone—hematologic cancer	1.39e-05	0.00017	CcSEcCtD
Regadenoson—Insomnia—Dexamethasone—hematologic cancer	1.39e-05	0.00017	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—hematologic cancer	1.39e-05	0.00017	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.39e-05	0.00017	CcSEcCtD
Regadenoson—Paraesthesia—Betamethasone—hematologic cancer	1.38e-05	0.000169	CcSEcCtD
Regadenoson—Paraesthesia—Dexamethasone—hematologic cancer	1.38e-05	0.000169	CcSEcCtD
Regadenoson—Discomfort—Prednisone—hematologic cancer	1.38e-05	0.000169	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—hematologic cancer	1.38e-05	0.000169	CcSEcCtD
Regadenoson—Rash—Gemcitabine—hematologic cancer	1.38e-05	0.000169	CcSEcCtD
Regadenoson—Dermatitis—Gemcitabine—hematologic cancer	1.38e-05	0.000169	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—hematologic cancer	1.38e-05	0.000169	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—hematologic cancer	1.38e-05	0.000168	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—hematologic cancer	1.38e-05	0.000168	CcSEcCtD
Regadenoson—Erythema—Methotrexate—hematologic cancer	1.37e-05	0.000168	CcSEcCtD
Regadenoson—Headache—Gemcitabine—hematologic cancer	1.37e-05	0.000168	CcSEcCtD
Regadenoson—Nausea—Vincristine—hematologic cancer	1.37e-05	0.000168	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CCR7—hematologic cancer	1.37e-05	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL13—hematologic cancer	1.37e-05	0.00128	CbGpPWpGaD
Regadenoson—Flushing—Epirubicin—hematologic cancer	1.37e-05	0.000167	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—hematologic cancer	1.37e-05	0.000167	CcSEcCtD
Regadenoson—Hypersensitivity—Prednisolone—hematologic cancer	1.36e-05	0.000166	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—hematologic cancer	1.36e-05	0.000166	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—IL3—hematologic cancer	1.36e-05	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NCOR2—hematologic cancer	1.36e-05	0.00127	CbGpPWpGaD
Regadenoson—Urticaria—Triamcinolone—hematologic cancer	1.35e-05	0.000165	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—hematologic cancer	1.35e-05	0.000164	CcSEcCtD
Regadenoson—Asthenia—Etoposide—hematologic cancer	1.34e-05	0.000164	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—hematologic cancer	1.34e-05	0.000164	CcSEcCtD
Regadenoson—Anaphylactic shock—Prednisone—hematologic cancer	1.34e-05	0.000164	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—hematologic cancer	1.34e-05	0.000164	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—SRC—hematologic cancer	1.34e-05	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL3RA—hematologic cancer	1.34e-05	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CRKL—hematologic cancer	1.34e-05	0.00125	CbGpPWpGaD
Regadenoson—Nausea—Mitoxantrone—hematologic cancer	1.34e-05	0.000163	CcSEcCtD
Regadenoson—Nausea—Irinotecan—hematologic cancer	1.34e-05	0.000163	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—hematologic cancer	1.33e-05	0.000163	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—hematologic cancer	1.33e-05	0.000163	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.33e-05	0.000162	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.33e-05	0.000162	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—hematologic cancer	1.32e-05	0.00124	CbGpPWpGaD
Regadenoson—Shock—Prednisone—hematologic cancer	1.32e-05	0.000161	CcSEcCtD
Regadenoson—Pain—Dexamethasone—hematologic cancer	1.32e-05	0.000161	CcSEcCtD
Regadenoson—Pain—Betamethasone—hematologic cancer	1.32e-05	0.000161	CcSEcCtD
Regadenoson—Nervous system disorder—Prednisone—hematologic cancer	1.32e-05	0.000161	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—RASGRP1—hematologic cancer	1.31e-05	0.00123	CbGpPWpGaD
Regadenoson—Tachycardia—Prednisone—hematologic cancer	1.31e-05	0.00016	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—hematologic cancer	1.31e-05	0.00122	CbGpPWpGaD
Regadenoson—Skin disorder—Prednisone—hematologic cancer	1.3e-05	0.000159	CcSEcCtD
Regadenoson—Nausea—Gemcitabine—hematologic cancer	1.3e-05	0.000159	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GRB2—hematologic cancer	1.3e-05	0.00122	CbGpPWpGaD
Regadenoson—Vomiting—Cisplatin—hematologic cancer	1.3e-05	0.000159	CcSEcCtD
Regadenoson—Hyperhidrosis—Prednisone—hematologic cancer	1.3e-05	0.000158	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—hematologic cancer	1.3e-05	0.000158	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—hematologic cancer	1.29e-05	0.000158	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—RGS2—hematologic cancer	1.29e-05	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—hematologic cancer	1.29e-05	0.00121	CbGpPWpGaD
Regadenoson—Rash—Cisplatin—hematologic cancer	1.29e-05	0.000157	CcSEcCtD
Regadenoson—Dermatitis—Cisplatin—hematologic cancer	1.29e-05	0.000157	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—NRAS—hematologic cancer	1.29e-05	0.0012	CbGpPWpGaD
Regadenoson—Erythema—Epirubicin—hematologic cancer	1.29e-05	0.000157	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—hematologic cancer	1.28e-05	0.000156	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—hematologic cancer	1.28e-05	0.000156	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—TRIO—hematologic cancer	1.28e-05	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TRH—hematologic cancer	1.28e-05	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CMA1—hematologic cancer	1.28e-05	0.00119	CbGpPWpGaD
Regadenoson—Ill-defined disorder—Methotrexate—hematologic cancer	1.28e-05	0.000156	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—hematologic cancer	1.27e-05	0.000156	CcSEcCtD
Regadenoson—Feeling abnormal—Dexamethasone—hematologic cancer	1.27e-05	0.000155	CcSEcCtD
Regadenoson—Feeling abnormal—Betamethasone—hematologic cancer	1.27e-05	0.000155	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—hematologic cancer	1.27e-05	0.000155	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—hematologic cancer	1.27e-05	0.000155	CcSEcCtD
Regadenoson—Gastrointestinal pain—Betamethasone—hematologic cancer	1.26e-05	0.000154	CcSEcCtD
Regadenoson—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.26e-05	0.000154	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—hematologic cancer	1.26e-05	0.000154	CcSEcCtD
Regadenoson—Hypersensitivity—Triamcinolone—hematologic cancer	1.25e-05	0.000153	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—AGO2—hematologic cancer	1.25e-05	0.00117	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPHK1—hematologic cancer	1.25e-05	0.00117	CbGpPWpGaD
Regadenoson—Angiopathy—Doxorubicin—hematologic cancer	1.24e-05	0.000151	CcSEcCtD
Regadenoson—Malaise—Methotrexate—hematologic cancer	1.24e-05	0.000151	CcSEcCtD
Regadenoson—Dizziness—Etoposide—hematologic cancer	1.24e-05	0.000151	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—LPAR1—hematologic cancer	1.24e-05	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HDAC9—hematologic cancer	1.24e-05	0.00116	CbGpPWpGaD
Regadenoson—Immune system disorder—Doxorubicin—hematologic cancer	1.24e-05	0.000151	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MAPK3—hematologic cancer	1.23e-05	0.00115	CbGpPWpGaD
Regadenoson—Mediastinal disorder—Doxorubicin—hematologic cancer	1.23e-05	0.00015	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—hematologic cancer	1.22e-05	0.00115	CbGpPWpGaD
Regadenoson—Urticaria—Betamethasone—hematologic cancer	1.22e-05	0.000149	CcSEcCtD
Regadenoson—Urticaria—Dexamethasone—hematologic cancer	1.22e-05	0.000149	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—H3F3B—hematologic cancer	1.22e-05	0.00114	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.22e-05	0.000149	CcSEcCtD
Regadenoson—Dizziness—Prednisolone—hematologic cancer	1.22e-05	0.000149	CcSEcCtD
Regadenoson—Asthenia—Triamcinolone—hematologic cancer	1.22e-05	0.000149	CcSEcCtD
Regadenoson—Abdominal pain—Dexamethasone—hematologic cancer	1.22e-05	0.000149	CcSEcCtD
Regadenoson—Abdominal pain—Betamethasone—hematologic cancer	1.22e-05	0.000149	CcSEcCtD
Regadenoson—Nausea—Cisplatin—hematologic cancer	1.21e-05	0.000148	CcSEcCtD
Regadenoson—Insomnia—Prednisone—hematologic cancer	1.21e-05	0.000148	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—hematologic cancer	1.21e-05	0.000148	CcSEcCtD
Regadenoson—Paraesthesia—Prednisone—hematologic cancer	1.21e-05	0.000147	CcSEcCtD
Regadenoson—Cough—Methotrexate—hematologic cancer	1.2e-05	0.000146	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—hematologic cancer	1.2e-05	0.000146	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—hematologic cancer	1.2e-05	0.00112	CbGpPWpGaD
Regadenoson—Ill-defined disorder—Epirubicin—hematologic cancer	1.19e-05	0.000146	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—hematologic cancer	1.19e-05	0.000145	CcSEcCtD
Regadenoson—Vomiting—Etoposide—hematologic cancer	1.19e-05	0.000145	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—hematologic cancer	1.19e-05	0.000145	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GRB2—hematologic cancer	1.18e-05	0.0011	CbGpPWpGaD
Regadenoson—Rash—Etoposide—hematologic cancer	1.18e-05	0.000144	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—hematologic cancer	1.18e-05	0.000144	CcSEcCtD
Regadenoson—Headache—Etoposide—hematologic cancer	1.17e-05	0.000143	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—hematologic cancer	1.17e-05	0.0011	CbGpPWpGaD
Regadenoson—Arthralgia—Methotrexate—hematologic cancer	1.17e-05	0.000143	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—hematologic cancer	1.17e-05	0.000143	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—hematologic cancer	1.17e-05	0.000143	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—hematologic cancer	1.17e-05	0.000142	CcSEcCtD
Regadenoson—Rash—Prednisolone—hematologic cancer	1.16e-05	0.000142	CcSEcCtD
Regadenoson—Dermatitis—Prednisolone—hematologic cancer	1.16e-05	0.000142	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.16e-05	0.000142	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CSF2—hematologic cancer	1.16e-05	0.00109	CbGpPWpGaD
Regadenoson—Malaise—Epirubicin—hematologic cancer	1.16e-05	0.000142	CcSEcCtD
Regadenoson—Headache—Prednisolone—hematologic cancer	1.16e-05	0.000141	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—hematologic cancer	1.16e-05	0.000141	CcSEcCtD
Regadenoson—Syncope—Epirubicin—hematologic cancer	1.15e-05	0.000141	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CNR2—hematologic cancer	1.14e-05	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDE4B—hematologic cancer	1.14e-05	0.00106	CbGpPWpGaD
Regadenoson—Palpitations—Epirubicin—hematologic cancer	1.14e-05	0.000139	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—hematologic cancer	1.13e-05	0.000138	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—FGF19—hematologic cancer	1.13e-05	0.00106	CbGpPWpGaD
Regadenoson—Dizziness—Triamcinolone—hematologic cancer	1.12e-05	0.000137	CcSEcCtD
Regadenoson—Cough—Epirubicin—hematologic cancer	1.12e-05	0.000137	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—hematologic cancer	1.12e-05	0.000137	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—hematologic cancer	1.12e-05	0.000137	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—JAK1—hematologic cancer	1.12e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCG—hematologic cancer	1.12e-05	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAC2—hematologic cancer	1.12e-05	0.00105	CbGpPWpGaD
Regadenoson—Convulsion—Epirubicin—hematologic cancer	1.11e-05	0.000136	CcSEcCtD
Regadenoson—Nausea—Etoposide—hematologic cancer	1.11e-05	0.000136	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—hematologic cancer	1.11e-05	0.000136	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—DKK1—hematologic cancer	1.11e-05	0.00104	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—hematologic cancer	1.11e-05	0.00104	CbGpPWpGaD
Regadenoson—Feeling abnormal—Prednisone—hematologic cancer	1.11e-05	0.000135	CcSEcCtD
Regadenoson—Asthenia—Dexamethasone—hematologic cancer	1.11e-05	0.000135	CcSEcCtD
Regadenoson—Asthenia—Betamethasone—hematologic cancer	1.11e-05	0.000135	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—hematologic cancer	1.1e-05	0.000135	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—STAT5B—hematologic cancer	1.1e-05	0.00103	CbGpPWpGaD
Regadenoson—Nervous system disorder—Methotrexate—hematologic cancer	1.1e-05	0.000134	CcSEcCtD
Regadenoson—Gastrointestinal pain—Prednisone—hematologic cancer	1.1e-05	0.000134	CcSEcCtD
Regadenoson—Nausea—Prednisolone—hematologic cancer	1.1e-05	0.000134	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—hematologic cancer	1.1e-05	0.000134	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—hematologic cancer	1.1e-05	0.000134	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—hematologic cancer	1.1e-05	0.000134	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—hematologic cancer	1.09e-05	0.000133	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—hematologic cancer	1.09e-05	0.000133	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.09e-05	0.000133	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—hematologic cancer	1.08e-05	0.000132	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—hematologic cancer	1.08e-05	0.000132	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—hematologic cancer	1.08e-05	0.00101	CbGpPWpGaD
Regadenoson—Vomiting—Triamcinolone—hematologic cancer	1.08e-05	0.000132	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—hematologic cancer	1.07e-05	0.000131	CcSEcCtD
Regadenoson—Rash—Triamcinolone—hematologic cancer	1.07e-05	0.000131	CcSEcCtD
Regadenoson—Dermatitis—Triamcinolone—hematologic cancer	1.07e-05	0.000131	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—ADCY7—hematologic cancer	1.07e-05	0.001	CbGpPWpGaD
Regadenoson—Syncope—Doxorubicin—hematologic cancer	1.07e-05	0.00013	CcSEcCtD
Regadenoson—Urticaria—Prednisone—hematologic cancer	1.07e-05	0.00013	CcSEcCtD
Regadenoson—Headache—Triamcinolone—hematologic cancer	1.06e-05	0.00013	CcSEcCtD
Regadenoson—Abdominal pain—Prednisone—hematologic cancer	1.06e-05	0.000129	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CSF2—hematologic cancer	1.06e-05	0.000987	CbGpPWpGaD
Regadenoson—Diarrhoea—Dexamethasone—hematologic cancer	1.05e-05	0.000129	CcSEcCtD
Regadenoson—Diarrhoea—Betamethasone—hematologic cancer	1.05e-05	0.000129	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—hematologic cancer	1.05e-05	0.000128	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCB1—hematologic cancer	1.05e-05	0.00395	CrCbGaD
Regadenoson—Anaphylactic shock—Epirubicin—hematologic cancer	1.05e-05	0.000128	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—hematologic cancer	1.05e-05	0.000128	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2RA—hematologic cancer	1.05e-05	0.00098	CbGpPWpGaD
Regadenoson—Loss of consciousness—Doxorubicin—hematologic cancer	1.05e-05	0.000128	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—XIAP—hematologic cancer	1.04e-05	0.000973	CbGpPWpGaD
Regadenoson—Cough—Doxorubicin—hematologic cancer	1.04e-05	0.000127	CcSEcCtD
Regadenoson—Shock—Epirubicin—hematologic cancer	1.03e-05	0.000126	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—hematologic cancer	1.03e-05	0.000126	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—hematologic cancer	1.03e-05	0.000126	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—hematologic cancer	1.03e-05	0.000125	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—hematologic cancer	1.02e-05	0.000125	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.02e-05	0.000125	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—hematologic cancer	1.02e-05	0.000124	CcSEcCtD
Regadenoson—Dizziness—Betamethasone—hematologic cancer	1.02e-05	0.000124	CcSEcCtD
Regadenoson—Dizziness—Dexamethasone—hematologic cancer	1.02e-05	0.000124	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—JAK1—hematologic cancer	1.02e-05	0.000953	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCG—hematologic cancer	1.02e-05	0.000953	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—hematologic cancer	1.02e-05	0.000952	CbGpPWpGaD
Regadenoson—Hyperhidrosis—Epirubicin—hematologic cancer	1.02e-05	0.000124	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—hematologic cancer	1.01e-05	0.000124	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—SH2B3—hematologic cancer	1.01e-05	0.000949	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SMARCA4—hematologic cancer	1.01e-05	0.000949	CbGpPWpGaD
Regadenoson—Arthralgia—Doxorubicin—hematologic cancer	1.01e-05	0.000124	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—hematologic cancer	1.01e-05	0.000124	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—hematologic cancer	1.01e-05	0.000124	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—hematologic cancer	1.01e-05	0.000123	CcSEcCtD
Regadenoson—Nausea—Triamcinolone—hematologic cancer	1.01e-05	0.000123	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GZMB—hematologic cancer	1.01e-05	0.000943	CbGpPWpGaD
Regadenoson—Paraesthesia—Methotrexate—hematologic cancer	1.01e-05	0.000123	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.01e-05	0.000123	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—hematologic cancer	1e-05	0.000122	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—hematologic cancer	1e-05	0.000122	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—hematologic cancer	9.97e-06	0.000122	CcSEcCtD
Regadenoson—Hypersensitivity—Prednisone—hematologic cancer	9.89e-06	0.000121	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CTNNA1—hematologic cancer	9.84e-06	0.00092	CbGpPWpGaD
Regadenoson—Hypotension—Epirubicin—hematologic cancer	9.81e-06	0.00012	CcSEcCtD
Regadenoson—Vomiting—Betamethasone—hematologic cancer	9.8e-06	0.00012	CcSEcCtD
Regadenoson—Vomiting—Dexamethasone—hematologic cancer	9.8e-06	0.00012	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—EIF4EBP1—hematologic cancer	9.78e-06	0.000915	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL3—hematologic cancer	9.78e-06	0.000915	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HSPB1—hematologic cancer	9.78e-06	0.000915	CbGpPWpGaD
Regadenoson—Rash—Betamethasone—hematologic cancer	9.72e-06	0.000119	CcSEcCtD
Regadenoson—Rash—Dexamethasone—hematologic cancer	9.72e-06	0.000119	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—hematologic cancer	9.71e-06	0.000119	CcSEcCtD
Regadenoson—Dermatitis—Dexamethasone—hematologic cancer	9.71e-06	0.000118	CcSEcCtD
Regadenoson—Dermatitis—Betamethasone—hematologic cancer	9.71e-06	0.000118	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—hematologic cancer	9.69e-06	0.000118	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—SDC1—hematologic cancer	9.67e-06	0.000905	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTHLH—hematologic cancer	9.67e-06	0.000905	CbGpPWpGaD
Regadenoson—Headache—Dexamethasone—hematologic cancer	9.66e-06	0.000118	CcSEcCtD
Regadenoson—Headache—Betamethasone—hematologic cancer	9.66e-06	0.000118	CcSEcCtD
Regadenoson—Asthenia—Prednisone—hematologic cancer	9.63e-06	0.000118	CcSEcCtD
Regadenoson—Pain—Methotrexate—hematologic cancer	9.59e-06	0.000117	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.57e-06	0.000117	CcSEcCtD
Regadenoson—Shock—Doxorubicin—hematologic cancer	9.56e-06	0.000117	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—hematologic cancer	9.53e-06	0.000116	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—IL2RA—hematologic cancer	9.51e-06	0.00089	CbGpPWpGaD
Regadenoson—Insomnia—Epirubicin—hematologic cancer	9.5e-06	0.000116	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—hematologic cancer	9.48e-06	0.000116	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—hematologic cancer	9.44e-06	0.000115	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—hematologic cancer	9.43e-06	0.000115	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—HRAS—hematologic cancer	9.42e-06	0.000881	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTGER4—hematologic cancer	9.42e-06	0.000881	CbGpPWpGaD
Regadenoson—Hyperhidrosis—Doxorubicin—hematologic cancer	9.39e-06	0.000115	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—LCK—hematologic cancer	9.37e-06	0.000876	CbGpPWpGaD
Regadenoson—Dyspnoea—Epirubicin—hematologic cancer	9.36e-06	0.000114	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—hematologic cancer	9.33e-06	0.000114	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—hematologic cancer	9.25e-06	0.000113	CcSEcCtD
Regadenoson—Diarrhoea—Prednisone—hematologic cancer	9.19e-06	0.000112	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—H3F3A—hematologic cancer	9.18e-06	0.000859	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Methotrexate—hematologic cancer	9.17e-06	0.000112	CcSEcCtD
Regadenoson—Nausea—Dexamethasone—hematologic cancer	9.16e-06	0.000112	CcSEcCtD
Regadenoson—Nausea—Betamethasone—hematologic cancer	9.16e-06	0.000112	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—hematologic cancer	9.08e-06	0.000111	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.06e-06	0.000111	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—IL6—hematologic cancer	9.02e-06	0.000843	CbGpPWpGaD
Regadenoson—Pain—Epirubicin—hematologic cancer	8.98e-06	0.00011	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PRKCZ—hematologic cancer	8.93e-06	0.000835	CbGpPWpGaD
Regadenoson—Urticaria—Methotrexate—hematologic cancer	8.91e-06	0.000109	CcSEcCtD
Regadenoson—Dizziness—Prednisone—hematologic cancer	8.88e-06	0.000108	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—hematologic cancer	8.87e-06	0.000108	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.85e-06	0.000108	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—hematologic cancer	8.79e-06	0.000107	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—hematologic cancer	8.73e-06	0.000816	CbGpPWpGaD
Regadenoson—Paraesthesia—Doxorubicin—hematologic cancer	8.72e-06	0.000106	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—hematologic cancer	8.66e-06	0.000106	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—hematologic cancer	8.65e-06	0.000106	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—hematologic cancer	8.64e-06	0.000105	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PARP1—hematologic cancer	8.62e-06	0.000807	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Epirubicin—hematologic cancer	8.59e-06	0.000105	CcSEcCtD
Regadenoson—Vomiting—Prednisone—hematologic cancer	8.54e-06	0.000104	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—FBXW7—hematologic cancer	8.48e-06	0.000793	CbGpPWpGaD
Regadenoson—Rash—Prednisone—hematologic cancer	8.46e-06	0.000103	CcSEcCtD
Regadenoson—Dermatitis—Prednisone—hematologic cancer	8.46e-06	0.000103	CcSEcCtD
Regadenoson—Headache—Prednisone—hematologic cancer	8.41e-06	0.000103	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.39e-06	0.000102	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—hematologic cancer	8.34e-06	0.000102	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CXCR4—hematologic cancer	8.32e-06	0.000778	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HDAC2—hematologic cancer	8.32e-06	0.000778	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—hematologic cancer	8.32e-06	0.000778	CbGpPWpGaD
Regadenoson—Pain—Doxorubicin—hematologic cancer	8.31e-06	0.000101	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—hematologic cancer	8.3e-06	0.000101	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—hematologic cancer	8.27e-06	0.000101	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CBL—hematologic cancer	8.11e-06	0.000758	CbGpPWpGaD
Regadenoson—Asthenia—Methotrexate—hematologic cancer	8.05e-06	9.82e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—IL3—hematologic cancer	8.02e-06	0.00075	CbGpPWpGaD
Regadenoson—Feeling abnormal—Doxorubicin—hematologic cancer	8.01e-06	9.77e-05	CcSEcCtD
Regadenoson—Nausea—Prednisone—hematologic cancer	7.97e-06	9.73e-05	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—hematologic cancer	7.94e-06	9.69e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—hematologic cancer	7.92e-06	0.000741	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTPN1—hematologic cancer	7.89e-06	0.000738	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTPN11—hematologic cancer	7.79e-06	0.000728	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RASGRP1—hematologic cancer	7.76e-06	0.000726	CbGpPWpGaD
Regadenoson—Hypersensitivity—Epirubicin—hematologic cancer	7.74e-06	9.44e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—HSP90AA1—hematologic cancer	7.73e-06	0.000723	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SYK—hematologic cancer	7.73e-06	0.000723	CbGpPWpGaD
Regadenoson—Urticaria—Doxorubicin—hematologic cancer	7.72e-06	9.42e-05	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—hematologic cancer	7.68e-06	9.37e-05	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—hematologic cancer	7.68e-06	9.37e-05	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CD—hematologic cancer	7.67e-06	0.000718	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CREB1—hematologic cancer	7.54e-06	0.000706	CbGpPWpGaD
Regadenoson—Asthenia—Epirubicin—hematologic cancer	7.53e-06	9.19e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—STAT1—hematologic cancer	7.46e-06	0.000698	CbGpPWpGaD
Regadenoson—Dizziness—Methotrexate—hematologic cancer	7.42e-06	9.05e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CCL2—hematologic cancer	7.38e-06	0.00069	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6R—hematologic cancer	7.36e-06	0.000688	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3R1—hematologic cancer	7.24e-06	0.000678	CbGpPWpGaD
Regadenoson—Diarrhoea—Epirubicin—hematologic cancer	7.18e-06	8.77e-05	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—hematologic cancer	7.16e-06	8.73e-05	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—hematologic cancer	7.13e-06	8.7e-05	CcSEcCtD
Regadenoson—Rash—Methotrexate—hematologic cancer	7.07e-06	8.63e-05	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—hematologic cancer	7.07e-06	8.62e-05	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—JAK2—hematologic cancer	7.04e-06	0.000659	CbGpPWpGaD
Regadenoson—Headache—Methotrexate—hematologic cancer	7.03e-06	8.58e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—MAP2K1—hematologic cancer	7.01e-06	0.000656	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRB2—hematologic cancer	6.98e-06	0.000653	CbGpPWpGaD
Regadenoson—Asthenia—Doxorubicin—hematologic cancer	6.97e-06	8.51e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CD—hematologic cancer	6.97e-06	0.000652	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFA—hematologic cancer	6.96e-06	0.000651	CbGpPWpGaD
Regadenoson—Dizziness—Epirubicin—hematologic cancer	6.94e-06	8.47e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—KITLG—hematologic cancer	6.86e-06	0.000642	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT5A—hematologic cancer	6.71e-06	0.000627	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	6.69e-06	0.000625	CbGpPWpGaD
Regadenoson—Vomiting—Epirubicin—hematologic cancer	6.68e-06	8.15e-05	CcSEcCtD
Regadenoson—Nausea—Methotrexate—hematologic cancer	6.66e-06	8.13e-05	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—hematologic cancer	6.65e-06	8.11e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CDKN2B—hematologic cancer	6.65e-06	0.000622	CbGpPWpGaD
Regadenoson—Rash—Epirubicin—hematologic cancer	6.62e-06	8.08e-05	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—hematologic cancer	6.61e-06	8.07e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3R1—hematologic cancer	6.58e-06	0.000615	CbGpPWpGaD
Regadenoson—Headache—Epirubicin—hematologic cancer	6.58e-06	8.03e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CD86—hematologic cancer	6.43e-06	0.000601	CbGpPWpGaD
Regadenoson—Dizziness—Doxorubicin—hematologic cancer	6.42e-06	7.84e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—JAK2—hematologic cancer	6.39e-06	0.000598	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HES1—hematologic cancer	6.34e-06	0.000593	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NCOR1—hematologic cancer	6.3e-06	0.00059	CbGpPWpGaD
Regadenoson—Nausea—Epirubicin—hematologic cancer	6.24e-06	7.61e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CSF2—hematologic cancer	6.23e-06	0.000583	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF1—hematologic cancer	6.23e-06	0.000583	CbGpPWpGaD
Regadenoson—Vomiting—Doxorubicin—hematologic cancer	6.18e-06	7.54e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—FOXO1—hematologic cancer	6.14e-06	0.000575	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2—hematologic cancer	6.14e-06	0.000574	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFRB—hematologic cancer	6.13e-06	0.000574	CbGpPWpGaD
Regadenoson—Rash—Doxorubicin—hematologic cancer	6.13e-06	7.47e-05	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—hematologic cancer	6.12e-06	7.47e-05	CcSEcCtD
Regadenoson—Headache—Doxorubicin—hematologic cancer	6.09e-06	7.43e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CB—hematologic cancer	6.07e-06	0.000568	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFRA—hematologic cancer	6.04e-06	0.000565	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCG—hematologic cancer	6.02e-06	0.000563	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAK1—hematologic cancer	6.02e-06	0.000563	CbGpPWpGaD
Regadenoson—Nausea—Doxorubicin—hematologic cancer	5.77e-06	7.04e-05	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—IL2RA—hematologic cancer	5.62e-06	0.000526	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL2—hematologic cancer	5.58e-06	0.000522	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TERT—hematologic cancer	5.56e-06	0.00052	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFB—hematologic cancer	5.42e-06	0.000507	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TSC2—hematologic cancer	5.3e-06	0.000496	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR3—hematologic cancer	5.1e-06	0.000477	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK14—hematologic cancer	5.05e-06	0.000472	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ESR1—hematologic cancer	4.95e-06	0.000463	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FN1—hematologic cancer	4.89e-06	0.000458	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BAD—hematologic cancer	4.83e-06	0.000452	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NFKBIA—hematologic cancer	4.83e-06	0.000452	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH1—hematologic cancer	4.79e-06	0.000448	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CD80—hematologic cancer	4.69e-06	0.000439	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—hematologic cancer	4.68e-06	0.000438	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KIT—hematologic cancer	4.68e-06	0.000438	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NRAS—hematologic cancer	4.68e-06	0.000438	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTPN11—hematologic cancer	4.6e-06	0.00043	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK3—hematologic cancer	4.48e-06	0.000419	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CREB1—hematologic cancer	4.46e-06	0.000417	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BRAF—hematologic cancer	4.4e-06	0.000412	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL2—hematologic cancer	4.36e-06	0.000408	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6R—hematologic cancer	4.35e-06	0.000407	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CREBBP—hematologic cancer	4.34e-06	0.000406	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAP2K1—hematologic cancer	4.14e-06	0.000388	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CD—hematologic cancer	4.12e-06	0.000385	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	4.08e-06	0.000381	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—hematologic cancer	4.03e-06	0.000377	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF2—hematologic cancer	3.94e-06	0.000369	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3R1—hematologic cancer	3.89e-06	0.000364	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAK2—hematologic cancer	3.78e-06	0.000353	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—hematologic cancer	3.7e-06	0.000346	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MDM2—hematologic cancer	3.69e-06	0.000345	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CB—hematologic cancer	3.59e-06	0.000336	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTOR—hematologic cancer	3.59e-06	0.000336	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRAS—hematologic cancer	3.42e-06	0.00032	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1B—hematologic cancer	3.37e-06	0.000315	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—hematologic cancer	3.33e-06	0.000311	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—hematologic cancer	3.3e-06	0.000309	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL2—hematologic cancer	3.29e-06	0.000308	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—hematologic cancer	3.28e-06	0.000307	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—hematologic cancer	3.21e-06	0.0003	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUN—hematologic cancer	3.2e-06	0.0003	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1A—hematologic cancer	3.11e-06	0.000291	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTEN—hematologic cancer	3.1e-06	0.00029	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK8—hematologic cancer	3.03e-06	0.000284	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—hematologic cancer	3.02e-06	0.000283	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EP300—hematologic cancer	2.96e-06	0.000277	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SRC—hematologic cancer	2.87e-06	0.000269	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—hematologic cancer	2.8e-06	0.000262	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—hematologic cancer	2.77e-06	0.000259	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NRAS—hematologic cancer	2.77e-06	0.000259	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK3—hematologic cancer	2.65e-06	0.000248	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—hematologic cancer	2.58e-06	0.000241	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFB1—hematologic cancer	2.57e-06	0.00024	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—hematologic cancer	2.38e-06	0.000223	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—hematologic cancer	2.19e-06	0.000205	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—hematologic cancer	2.12e-06	0.000198	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRAS—hematologic cancer	2.02e-06	0.000189	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—hematologic cancer	1.94e-06	0.000181	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—hematologic cancer	1.79e-06	0.000167	CbGpPWpGaD
